|drug319||Attention control Wiki||1.00|
|drug2086||Motivational social support from nurse with additional support from significant other Wiki||1.00|
|drug2085||Motivational social support from nurse Wiki||1.00|
|D003324||Coronary Artery Disease NIH||0.50|
|D006331||Heart Diseases NIH||0.38|
|D009203||Myocardial Ischemia NIH||0.29|
There is one clinical trial.
This study is a randomized, open-label, parallel groups multi-centered trial were participants are assigned to either an intervention arm ( a combination of Favipiravir and Hydroxychloroquin) or standard of care.
Description: The primary endpoint is the time to clinical improvement, defined as the time from the randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever came first.Measure: Clinical Improvement Time: 28 days
Description: PCR test negative conversion days from positive to negative.Measure: Viral shedding Time: 28 days
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports